219 related articles for article (PubMed ID: 20012173)
21. General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study.
Bach T; Jiang Y; Zhang X; An G
J Clin Pharmacol; 2019 Mar; 59(3):394-405. PubMed ID: 30387863
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers.
Krzyzanski W; Wyska E
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):637-45. PubMed ID: 18071675
[TBL] [Abstract][Full Text] [Related]
23. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.
Yan X; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):141-6. PubMed ID: 22215144
[TBL] [Abstract][Full Text] [Related]
24. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
[TBL] [Abstract][Full Text] [Related]
25. Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-γ-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic Dosing.
Cai W; Leil TA; Gibiansky L; Krishna M; Zhang H; Gu H; Sun H; Throup J; Banerjee S; Girgis I
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):689-698. PubMed ID: 32068354
[TBL] [Abstract][Full Text] [Related]
26. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
[TBL] [Abstract][Full Text] [Related]
27. Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target.
Tang C; Prueksaritanont T
Pharm Res; 2011 Oct; 28(10):2447-57. PubMed ID: 21614635
[TBL] [Abstract][Full Text] [Related]
28. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
Olsson-Gisleskog P; Jacqmin P; Perez-Ruixo JJ
Clin Pharmacokinet; 2007; 46(2):159-73. PubMed ID: 17253886
[TBL] [Abstract][Full Text] [Related]
30. Target-mediated drug disposition and dynamics.
Mager DE
Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
[TBL] [Abstract][Full Text] [Related]
31. A Pharmacometrics Model to Characterize a New Type of Target-Mediated Drug Disposition (TMDD) - Nonlinear Pharmacokinetics of Small-Molecule PF-07059013 Mediated By Its High-capacity Pharmacological Target Hemoglobin With Positive Cooperative Binding.
Xu M; An G
AAPS J; 2023 Apr; 25(3):41. PubMed ID: 37055588
[TBL] [Abstract][Full Text] [Related]
32. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.
Mager DE; Krzyzanski W
Pharm Res; 2005 Oct; 22(10):1589-96. PubMed ID: 16180117
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model.
Odani A; Hashimoto Y; Takayanagi K; Otsuki Y; Koue T; Takano M; Yasuhara M; Hattori H; Furusho K; Inui K
Biol Pharm Bull; 1996 Mar; 19(3):444-8. PubMed ID: 8924916
[TBL] [Abstract][Full Text] [Related]
34. Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model.
Ternant D; Le Tilly O; Picon L; Moussata D; Passot C; Bejan-Angoulvant T; Desvignes C; Mulleman D; Goupille P; Paintaud G
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834236
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors.
Ma P; Yang BB; Wang YM; Peterson M; Narayanan A; Sutjandra L; Rodriguez R; Chow A
J Clin Pharmacol; 2009 Oct; 49(10):1142-56. PubMed ID: 19723673
[TBL] [Abstract][Full Text] [Related]
36. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
[TBL] [Abstract][Full Text] [Related]
37. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.
Yan X; Chen Y; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):543-60. PubMed ID: 22926955
[TBL] [Abstract][Full Text] [Related]
38. Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice.
Abraham AK; Kagan L; Kumar S; Mager DE
J Pharmacol Exp Ther; 2010 Jul; 334(1):327-32. PubMed ID: 20406858
[TBL] [Abstract][Full Text] [Related]
39. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
[TBL] [Abstract][Full Text] [Related]
40. Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
Wu N; Katz DA; An G
Clin Pharmacokinet; 2023 Sep; 62(9):1275-1288. PubMed ID: 37452998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]